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Commentary
Response Expectancy and the Response to Antidepressant Medication
Irving Kirsch ⁎
Program in Placebo Studies, Harvard Medical School, USA
Previous studies have shown that perceived treatment assignment
(placebo vs drug) is associated with response to SSRIs (e.g., Chen et
al., 2011). However, interpretation of those results is hampered by the
fact that they are correlational. Thus, treatment outcomemay be affect-
ing guesses about treatment assignment rather than guesses affecting
outcome. The Faria et al. study in EBioMedicine is virtually unique in
its use of an experimental manipulation, thereby allowing inferences
of causality (Faria et al., 2017). The results are clear and compelling. Al-
though escitalopram alleviated escitalopram even when given covertly,
its effectswere two to three times greaterwhen administered knowing-
ly. Indeed, the effect size for overt versus covert administration of this
SSRI, as calculated from the data in Table 2, is very large (d = 1.2),
three times as large as the small tomoderate drug-placebo effect size re-
ported in a recent meta-analysis for the treatment of social anxiety dis-
order by SSRIs and SNRIs (d= 0.39) (Sugarman et al., 2017).
These data have enormous clinical implications. They indicate that
the information given to patients about SSRIs can have a greater impact
than the drugs themselves. Data from other studies suggest that clini-
cianwarmth and empathy can impact both improvement and expected
improvement in clinical conditions (He et al., 2017; Kaptchuk et al.,
2008). Taken together, these data underline the importance of training
clinicians in how to communicate most effectively with patients. It is
not only the speciﬁc treatment that is important in producing favorable
health outcomes; it is also the clinician's ability to establish a therapeu-
tic alliance and promote positive response expectancies.
Placebo effects and speciﬁc drug effects are components of the total
response when a drug or other active treatment is given. Data and opin-
ion are mixed on whether these effects are additive. Speciﬁcally, do
non-drug aspects of treatment (e.g., knowledge that one is receiving a
treatment) increase the response to the treatment. The logic of random-
ized clinical trials (RCTs) implies an assumption that drug and placebo
effects are additive, but some writers have challenged this assumption
(e.g., Lund et al., 2014) If they are not additive, they say, then conven-
tional RCTs might underestimate the speciﬁc drug component of the
treatment response.
The data from the Faria et al. study are pertinent to the issue of addi-
tivity. In particular, the size of the expectancy effect they obtained is so
large that an even larger effect in placebo arms seemsunlikely. Indeed, if
there is a signiﬁcant interaction, it may be due to the placebo effect
being larger when a real drug is given than when a placebo is given,
as has been reported in a study of analgesic medication (Schenk et al.,
2014). Nevertheless, the Faria et al. study was not designed to test addi-
tivity. As the .authors indicate, the gold standard for assessing additivity
is by use of the balanced placebo design (Marlatt and Rohsenow, 1980).
The balanced placebo design comprises four arms. It is a 2 × 2 design in
whichwhat participants are told (that they are receive an active drug or
a placebo) is crossed with what they actually receive (drug or placebo).
It has been used to reveal additive and non-additive relations between
drug content and expectancies with respect to responses associated
with alcohol, caffeine, and analgesic medication, among other sub-
stances, but has not been evaluatedwith respect to antidepressantmed-
ications. The Faria et al. study contains two of the cells of the balanced
placebo (told drug – get drug; told placebo – get drug). Adding the
two remaining cells (told placebo– get drug; told placebo – get placebo)
would be the next step in solving the puzzle of additivity.
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